Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer-Reference-Cited by-同舟云学术

Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer

Published:2022-01 Issue:1 Volume:15 Page:101298
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Lin Xuan,Chen Hedan,Xie Ying,Zhou Xue,Wang Yun,Zhou Jing,Long Shiqi,Hu Zuquan,Zhang Shichao,Qiu Wei,Zeng Zhu,Liu Lina

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference43 articles.

1. Immunotherapy in triple‑negative breast cancer;Katz;Med. Oncol.,2017

2. Rational combination of immunotherapy for triple negative breast cancer treatment;Li;Chin. Clin. Oncol.,2017

3. Recent advances in triple negative breast cancer: the immunotherapy era;Marra;BMC. Med.,2019

4. Oncology meets immunology: the cancer-immunity cycle;Chen;Immunity,2013

5. Enhancing dendritic cell therapy in solid tumors with immunomodulating conventional treatment;Belderbos;Mol. Ther. Oncolytics.,2019

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current advances in non-viral nanoparticle-based gene therapy for effective management of cancer;Journal of Drug Delivery Science and Technology;2024-10

2. Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer;Current Pharmaceutical Biotechnology;2024-07-31

3. Breaking Barriers: The Promise and Challenges of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer;Biomedicines;2024-02-05

4. MUC1 and MUC16: critical for immune modulation in cancer therapeutics;Frontiers in Immunology;2024-02-01

5. Advances in Monoclonal Antibody Therapies for Triple-Negative Breast Cancer: Immunotherapeutic and Targeted Strategies;Current Molecular Medicine;2024-01-26